What it is
PEG-MGF is a pegylated mechano-growth factor idea studied for muscle-repair research. Human protocol data are not established.
Evidence boundary
Preclinical / speculative. Do not present a human dosing schedule as an established standard.
Trial evidence
No verified human trial found.
Preparation and measurement
Reconstitution: 2 mg vial + 3 mL BAC = 0.67 mg/mL.
Concentration matches.
Reference schedule
| Phase | Dose | Draw / measure | Frequency | Weekly total |
|---|---|---|---|---|
| Weeks 1–2 (titration) | 200 mcg | 30 U (0.3 mL) | Once daily | 1.4 mg/week |
| Weeks 3–4 | 300 mcg | 45 U (0.45 mL) | Once daily | 2.1 mg/week |
| Weeks 5–6 | 400 mcg | 60 U (0.6 mL) | Once daily | 2.8 mg/week |
| Weeks 7–8 (target) | 500 mcg | 75 U (0.75 mL) | Once daily | 3.5 mg/week |
Weeks 1–2 (titration)
- Dose
- 200 mcg
- Draw / measure
- 30 U (0.3 mL)
- Frequency
- Once daily
- Weekly total
- 1.4 mg/week
Weeks 3–4
- Dose
- 300 mcg
- Draw / measure
- 45 U (0.45 mL)
- Frequency
- Once daily
- Weekly total
- 2.1 mg/week
Weeks 5–6
- Dose
- 400 mcg
- Draw / measure
- 60 U (0.6 mL)
- Frequency
- Once daily
- Weekly total
- 2.8 mg/week
Weeks 7–8 (target)
- Dose
- 500 mcg
- Draw / measure
- 75 U (0.75 mL)
- Frequency
- Once daily
- Weekly total
- 3.5 mg/week
Weekly totals apply only during the active phase.
Titration rules
-
Twice-weekly schedule:
-
Light (100 mcg, 2×/week): Conservative dose.
-
Standard (200 mcg, 2×/week): Common research dose.
-
Higher (300 mcg, 2×/week): Heavy training / acute injury research.
-
Timing: Inject within 1 hour post-training to leverage the satellite cell activation window. Sub-Q or IM near target muscle group.
-
Cycle: 8–12 weeks active training cycle, then 4-week break.
-
Whether a source is actually human data
-
Muscle-repair claims in the source literature
-
Limited safety information
-
Injection-site reactions
Practical rules
- Do not use animal-model dosing as human guidance.
- Rotate sites.
- Pair any muscle-repair work with resistance training, protein, and sleep.